STOCK TITAN

Kinnate Biopharma Inc. - $KNTE STOCK NEWS

Welcome to our dedicated page for Kinnate Biopharma news (Ticker: $KNTE), a resource for investors and traders seeking the latest updates and insights on Kinnate Biopharma stock.

Kinnate Biopharma Inc. (Nasdaq: KNTE) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focusing on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. Founded in 2018, Kinnate aims to address known oncogenic drivers for which there are currently no approved targeted therapies, and to overcome the limitations of existing cancer treatments, such as non-responsiveness and resistance.

The company's lead product candidate is EXARAFENIB, an investigational pan-RAF inhibitor targeting cancers with BRAF and NRAS-driven alterations. Another key candidate is KIN-3248, designed to treat cancers with FGFR2 and FGFR3 alterations. These candidates are part of the company's broader pipeline driven by the Kinnate Discovery Engine, which prioritizes high selectivity, optimized pharmaceutical properties, broad genetic alteration coverage, overcoming resistance, and brain penetration.

Recent achievements include FDA clearance for the IND application for KIN-7136, a brain-penetrant MEK inhibitor, and ongoing clinical trials for the exarafenib plus binimetinib combination. However, Kinnate has announced a strategic reprioritization plan, pausing the development of KIN-7136 and exploring strategic alternatives for exarafenib monotherapy and KIN-3248.

Financially, Kinnate reported having approximately $204.3 million in cash as of June 2023, projected to fund operations into the second quarter of 2026. Furthermore, the company has announced a workforce restructuring to align with its refined focus, aiming to retain around 28 full-time employees.

In terms of partnerships, Kinnate recently agreed to sell its investigational pan-RAF inhibitor, exarafenib, to Pierre Fabre Laboratories. This agreement is expected to expand the reach of Kinnate’s programs globally and maximize value for shareholders.

For more information, visit Kinnate.com and follow the company on LinkedIn to stay updated on their latest initiatives and corporate developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.63%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.23%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.43%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.18%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.94%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
none

FAQ

What does Kinnate Biopharma Inc. specialize in?

Kinnate Biopharma specializes in the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers.

What are Kinnate's lead product candidates?

Kinnate's lead product candidates are exarafenib, targeting BRAF and NRAS-driven cancers, and KIN-3248, targeting FGFR2 and FGFR3 alterations.

Where is Kinnate Biopharma headquartered?

Kinnate Biopharma is headquartered in San Diego, California.

What recent achievements has Kinnate reported?

Recent achievements include FDA clearance for the IND application for KIN-7136 and ongoing clinical trials for the exarafenib and binimetinib combination.

What strategic changes has Kinnate made recently?

Kinnate has announced a strategic reprioritization plan, pausing development of KIN-7136 and exploring strategic alternatives for exarafenib monotherapy and KIN-3248.

What is Kinnate's financial condition?

As of June 2023, Kinnate reported having approximately $204.3 million in cash, projected to fund operations into the second quarter of 2026.

What recent partnerships has Kinnate entered into?

Kinnate has agreed to sell its investigational pan-RAF inhibitor, exarafenib, to Pierre Fabre Laboratories to expand the reach of its programs globally.

How many employees does Kinnate plan to retain?

After a planned workforce restructuring, Kinnate expects to retain around 28 full-time employees.

Where can I find more information about Kinnate Biopharma?

For more information, visit Kinnate's website at https://kinnate.com and follow the company's LinkedIn profile for updates.

What is the Kinnate Discovery Engine?

The Kinnate Discovery Engine is the company's platform for developing small molecule candidates with high selectivity, optimized properties, broad genetic alteration coverage, overcoming resistance, and brain penetration.

Kinnate Biopharma Inc.

Nasdaq:KNTE

KNTE Rankings

KNTE Stock Data

124.99M
22.68M
0.16%
82.58%
0.99%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco